Sarasota, FL, Jan. 02, 2017 -- According to a new report published by Zion Market Research titled “Active Pharmaceutical Ingredients Market by API Synthesis (Biotech API, Synthetic Chemical API, and HPAPI), by Type of Manufacturing (Contract Manufacturing and In-House API Manufacturing), by Type of API (Synthetic API and Biological API), by Drug Type (Branded Drugs, Generic Drugs and OTC Drugs), for Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal and Other Application - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”, global active pharmaceutical ingredient market was valued at USD 148.22 billion in 2015, is expected to reach USD 213.84 billion in 2021 and is anticipated to grow at a CAGR of 6.3% between 2016 and 2021.
APIs are frequently referred as "bulk pharmaceuticals”. The active pharmaceutical ingredient is a biologically active portion of any pharmaceutical drug. Occasionally, API needs cofactor in order to attain specific effects on the body. Some active pharmaceutical ingredients are unidentified and therefore need additional substances, which can work in combination with the API to generate the required medicinal effect on the body. In herbal medicines, the API is generally a mixture of various substances, which act collectively on the body.
Request free Sample copy of Active pharmaceutical ingredient Market @ https://www.zionmarketresearch.com/sample/active-pharmaceutical-ingredients-market
The market for API is expected to have the highest growth rate in the forecast period. The increasing prevalence of diabetes, neurological disorders, and other chronic diseases are the major driving factor of the global API market. One of the key drivers of the API market is an increase in the outsourcing of active pharmaceutical ingredients manufactured by pharmaceutical companies which are done to reduce both manufacturing and infrastructure costs. Such outsourced manufacturing activities are carried out by low-cost vendors in the Asia Pacific region.
However, strict regulations are one of the major challenges faced by the global API market. Such regulations are predominantly well defined in developed regions such as North America and Europe. Vendors in this market space are supposed to obey the detailed procedures prior to product commercialization.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/active-pharmaceutical-ingredients-market
The global API market is segmented based on API synthesis, type of manufacturing, and type of API, application and by region. Depending on synthesis market is classified into biotech API, synthetic chemical API, and HPAPI. On the basis of the type of drug, the market is segmented into branded drugs, generic drugs, and OTC (Over the Counter) drugs. The branded drug segment accounted for the largest share in 2015. Different therapeutic application of the API market includes cardiology, oncology, anti-inflammatory, gastrointestinal and others. The oncology segment is anticipated to grow at the highest growth rate in coming years due to increasing prevalence of cancer worldwide.
North America is leading market for API and acquired the largest share in 2015. Asia-Pacific region is expected to emerge as fastest growing region due to low operation costs and high investments in medical research. Furthermore, the high cost of trained labor and energy are the most important factors that enforced European market to move their base to develop countries such as India and China.
Request a customized copy of report @ https://www.zionmarketresearch.com/custom/56
Sun Pharmaceuticals Industries Limited, Novartis International AG, BASF SE, Pfizer, Inc., Aurobindo, Albemarle Corporation, and Boehringer Ingelheim among others are some of the leading players in API market.
Browse the full "Active Pharmaceutical Ingredients Market by API Synthesis (Biotech API, Synthetic Chemical API, and HPAPI), by Type of Manufacturing (Contract Manufacturing and In-House API Manufacturing), by Type of API (Synthetic API and Biological API), by Drug type (Into Branded Drugs, Generic Drugs and OTC Drugs), for Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal and Other Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/active-pharmaceutical-ingredients-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Contact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: [email protected] Website: https://www.zionmarketresearch.com/


ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
OpenAI Explores Massive Funding Round at $750 Billion Valuation
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 



